



ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /JS/

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/P/T/O

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 2

Complete If Known

Application Number 10/521,513
Filing Date July 17, 2003
First Named Inventor Roy R. Lobb
Art Unit N/A
Examiner Name Not Yet Assigned J. Seharaseyon
Attorney Docket Number BII-001.01

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA*	US-5,908,626	06-01-1999	Chang et al.	
	AB*	US-6,127,332	10-03-2000	Goetz et al.	
	AC*	US-4,588,585	05-13-1986	Mark et al.	
	AD*	US-5,565,335	10-15-1996	Capon et al.	
	AE*	US-6,800,735-A1	10-05-2004	Whitty et al.	
	AF*	US-6,962,978-A1	11-08-2005	Pepinsky et al.	
	AG*	US-6,372,207	04-16-2002	Tepper et al.	
	AH*	US-5,906,816	05-25-1999	Soos et al.	
	AI*	US-6,060,450	05-09-2000	Soos et al.	
	AJ*	US-20030007969-A1	01-09-2003	Lobb et al.	
	AK*	US-20050214253-A1	09-29-2005	Whitty et al.	
	AL*	US-20050107277-A1	05-19-2005	Lin et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ² -Number ³ -Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁴
	BA	WO-01/77137	10-18-2001			
	BB	WO-00/23472	04-27-2000			
	BC	WO-00/23114	04-27-2000			
	BD	WO-98/28007	07-02-1998			
	BE	WO-04/28472	04-08-2004			
	BF	WO-03/61577	07-31-2003			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.58(a)(2)(ii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP §901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST-16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CA	Schwartz, A. et al. "Prophylaxis and Therapy of Severe Lupus Nephritis by Interferon-beta Treatment." Kidney Blood Press. Res. 2001, Vol 24, No. 4-6, p. 218.	
	CB	International Search Report for PCT/US03/22440, mailed July 2, 2004.	
	CC	May and Sehgal. "On the Relationship Between Human Interferon Alpha 1 and Beta 1 Genes." J. Interferon Res. 1985, Vol. 5, p. 521-26.	

Examiner Signature /Jegatheesan Seharaseyon/ Date Considered 04/02/2008

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /JS/



PTO/SB/08a/b (07-05)
 Approved for use through 07/31/2006. OMB 055-0031
 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
 Under the Paperwork Reduction Project Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	2	of	2	Attorney Docket Number	BII-001.01
-------	---	----	---	------------------------	------------

Complete If Known

Application Number	10/521,513
Filing Date	July 17, 2003
First Named Inventor	Roy R. Lobb
Art Unit	N/A
Examiner Name	Not Yet Assigned J. Seharaseyon
Attorney Docket Number	BII-001.01

CD	N. Kayagaki et al. "Type I Interferons (IFNs) Regulate Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL) Expression on Human T Cells: A Novel Mechanism for the Antitumor Effects of Type I IFNs." J. Exp. Med. Vol. 189, No. 9, p. 1451-60.
CE	V.J. Cavanaugh et al. "Inhibition of Hepatitis B virus Replication During Adenovirus and Cytomegalovirus Infections In Transgenic Mice." J. Virol. 1998, Vol. 72, No. 4, p. 2630-37.
CF	T. Vial et al. "Immune-mediated Side-Effects Of Cytokines In Humans." Toxicology. 1995, Vol. 105, No. 1, p. 31-57.
CG	J. Imanishi "Interferon-alpha, Beta, Gamma." Gan To Kagaku Ryoho. 1994, Vol. 21, No. 16, p. 2853-58. Abstract.
CH	T. Ueda et al. "Clinical and Histological Observation of HBV Glomerulonephritis Treated With Interferon-beta." Nippon Jinzo Gakkai Shi. 1990, Vol. 32, No. 11, p. 1153-9. Abstract.
CI	J.J. Rinehart et al. "Phase I/II trial of Interferon-Beta-Serine In Patients With Renal Cell Carcinoma: Immunological And Biological Effects." Cancer Res. 1987, Vol. 47, No. 9, p. 2481-85.
CJ	H. Nakayama et al. "Pharmacokinetic Study of Human Natural Beta-Interferon In Patients With End-Stage Renal Failure." Clin. Nephrol. 2001, Vol. 56, No. 5, p. 382-86.
CK	Y. Shiratori et al. "Different Turnover Rate Of Hepatitis C Virus Clearance by Different Treatment Regimen Using Interferon-beta." J. Hepatol. 2000, Vol. 33, No. 2, p. 313-22.
CL	S.E. Krown. "Interferon Treatment Of Renal Cell Carcinoma. Current Status And Future Prospects." Cancer. 1987, Vol. 59, No. 3 Suppl., p. 647-51.
CM	S. Mani et al. "Recombinant Beta-Interferon In The Treatment Of Patients With Metastatic Renal Cell Carcinoma." Am. J. Clin. Oncol. 1996, Vol. 19, No. 2, p. 187-89.
CN	C. Scoponi et al. "Long-lasting Complete Remission Of Pulmonary Metastases Consequent To Renal Cell Carcinoma Obtained With Interferon-Beta Therapy: Review Of The Literature And A Case Report." Tumor. 1995, Vol. 81, No. 3, p. 201-3.
CO	E.C. Borden et al. "Biological and Clinical Effects of Interferon-Beta Ser at Two Doses." J Interferon Res. 1990, Vol. 10, No. 6, p. 559-70.
CP	M. Karpusas et al. "The Crystal Structure of Human Interferon-beta at 2.2-Angstrom Resolution." PNAS, 1997, Vol. 94, pp. 11813-18.
CQ	F.W.K. Tam et al. "Development of Scarring and Renal Failure in a Rat Model of Crescentic Glomerulonephritis." Nephrol. Dial. Transplant. 1999, Vol. 14, No. 7, p. 1658-66.
CR	A.R. Allen et al. "Endothelial Expression of VCAM-1 in Experimental Crescentic Nephritis and Effect Of Antibodies to Very Late Antigen-4 or VCAM-1 on Glomerular Injury." J. Immunol. 1999, Vol. 162, No. 9, p. 5519-27.

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Jegatheesan Seharaseyon/	Date Considered	04/02/2008
--------------------	---------------------------	-----------------	------------